Relevance of interleukin-1 receptor antagonist intron-2 polymorphism in ischemic stroke

Cerebrovascular Diseases

Volumn 15, Issue 4, 2003, Pages 276-281

  Seripa, Davide ^a   Dobrina, Aldo ^b   Margaglione, Maurizio ^a,c   Matera, Maria Giovanna ^a   Gravina, Carolina ^a   Vecile, Elena ^b   Fazio, Vito Michele ^a,d  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Atherosclerosis; Genetics; Interleukins; Risk factors; Stroke

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGE; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INTRON; ITALY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SURVIVAL;

ADULT; AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INTERLEUKIN-1; INTRONS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, INTERLEUKIN-1; SURVIVORS;

EID: 0037269189     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069497     Document Type: Article

References (38)

1. Munro JM, Cotran RS: The pathogenesis of atherosclerosis: Atherogenesis and inflammation. Lab Invest 1988;58:249-261.
2. Ross R: Mechanism of atherosclerosis - a review. Adv Nephrol Necker Hosp 1990;19:79-86.
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326:242-250.
4. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:310-318.
5. Alberts MJ: Genetics of cerebrovascular disease. Stroke 1990;21(suppl 11):III127-III130.
6. Pullicino P, Greenberg S, Trevisan M: Genetic stroke risk factors. Curr Opin Neurol 1997;10:58-63.
7. Elbaz A, Amarenco P: Genetic susceptibility and ischaemic stroke. Curr Opin Neurol 1999;12:47-55.
8. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA: Leukocytes and the risk of ischemic diseases. JAMA 1987;257:2318-2324.
9. Ridker PM, Hennekens CH: Hemostatic risk factors for coronary heart disease. Circulation 1991;83:1098-1100.
10. Heller RF, Chinn S, Pedoe HD, Rose G: How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project. Br Med J (Clin Res Ed) 1984;288:1409-1411.
11. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
12. Ross R: Atherosclerosis is an inflammatory disease. Am Heart J 1999;138(5Pt2):S419-S420.
13. Mach F, Schonbeck U, Sukhova GK, Atkins E, Libby P: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394:200-203.
14. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, Flavell RA: Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999;5:1313-1316.
15. Carr SC, Farb A, Pearce WH, Virmani R, Yao JS: Activated inflammatory cells are associated with plaque rupture in carotid artery stenosis. Surgery 1997;122:757-763.
16. Jander S, Sitzer M, Schumann R, Schroeter M, Siebler M, Steinmetz H, Stoll G: Inflammation in high-grade carotid stenosis: A possible role for macrophages and T cells in plaque destabilization. Stroke 1998;29:1625-1630.
17. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2147.
18. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM: Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 1996;16:1000-1006.
19. Moyer CF, Sajuthi D, Tulli H, Williams JK: Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am J Pathol 1991;138:951-960.
20. Sciacca FL, Ferri C, Vandenbroeck K, Veglia F, Gobbi C, Martinelli F, Franciotta D, Zaffaroni M, Marrosu M, Martino G, Martinelli V, Comi G, Canal N, Grimaldi LM: Relevance of interleukin-1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology 1999;52:1896-1898.
21. Katila H, Hanninen K, Hurme M: Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol Psychiatry 1999;4:179-181.
22. Hurme M, Santtila S: IL-1 receptor antagonist (IL-1Ra) plasma levels are coordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998;28:2598-2602.
23. Margaglione M, Celentano E, Grandone E, Vecchione G, Cappucci G, Giuliani N, Colaizzo D, Panico S, Mancini FP, Di Minno G: Deletion polymorphism in the angiotensin-converting enzyme gene in patients with a history of ischemic stroke. Arterioscler Thromb Vasc Biol 1996;16:304-309.
24. Margaglione M, Seripa D, Gravina C, Grandone E, Vecchione G, Cappucci G, Merla G, Papa S, Postiglione A, Di Minno G, Fazio VM: Prevalence of apolipoprotein E alleles in healthy subjects and survivors of ischemic stroke: An Italian Case-Control Study. Stroke 1998;29:399-403.
25. Margaglione M, D'Andrea G, Giuliani N, Brancaccio V, De Lucia D, Grandone E, De Stefano V, Tonali PA, Di Minno G: Inherited prothrombotic conditions and premature ischemic stroke: Sex difference in the association with factor V Leiden. Arterioscler Thromb Vasc Biol 1999;19:1751-1756.
26. Margaglione M, Di Minno G, Grandone E, Celentano E, Vecchione G, Cappucci G, Grilli M, Mancini FP, Postiglione A, Panico S, Mancini M: Plasma lipoprotein (a) levels in subjects attending a metabolic ward: Discrimination between individuals with and without a history of ischemic stroke. Arterioscler Thromb Vasc Biol 1996;16:120-128.
27. Anderson CS, Jamrozik KD, Broadhurst RJ, Stewart-Wynne EG: Predicting survival for 1 year among different subtypes of stroke: Results from the Perth Community Stroke Study. Stroke 1994;25:1935-1944.
28. di Giovine FS, Takhsh E, Blakemore AI, Duff GW: Single base polymorphism at -511 in the human interleukin-1 beta gene (IL-1 beta). Hum Mol Genet 1992;1:450.
29. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff WG: Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993;91:403-404.
30. Gerdes LU, Klausen IC, Sihm I, Faergeman O: Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genet Epidemiol 1992;9:155-167.
31. Casagrande JT, Pike MC, Smith PG: The power function of the 'exact' test for comparing two binominal distributions. Appl Stat 1978,27:176-180.
32. La mortalità in Italia nel periodo 1970-1992: Evoluzione e geografia. Ministero della Sanità, Roma.
33. Van den Velden PA, Reitsma PH: Amino acid dimorphism in IL-1A is detectable by PCR amplification. Hum Mol Genet 1993;2:1753.
34. Danis VA, Millington M, Hyland VJ, Grennan D: Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995;99:303-310.
35. Mansfield JC, Holden H, Tarlow JK, Di Giovine FS, McDowell TL, Wilson AG, Holdsworth CD, Duff GW: Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106:637-642.
36. Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, Jeffrey S, Kaski JC, Cumberland DC, Duff GW, Crossman DC: Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999;99:861-866.
37. Touzani O, Boutin H, Cuquet J, Rothwell N: Potential mechanism of interleukin-1 involvement in cerebral ischemia. J Neuroimmunol 1999;100:203-215.
38. Stoller DK, Grorud CB, Michalek V, Buchwald H: Reduction of atherosclerosis with nonsteroidal anti-inflammatory drugs. J Surg Res 1993;54:7-11.